HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Guest Access | Sign In via User Name/Password

This Article Full Text Free Full Text (PDF) Free Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Article Archive Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (15) Citing Articles via Google Scholar Google Scholar Articles by Ramsey, S. D. Search for Related Content PubMed PubMed Citation Articles by Ramsey, S. D.

Suboptimal Medical Therapy in COPD^*

Exploring the Causes and Consequences

^* From the Departments of Medicine and Health Services,

Correspondence to: Scott D. Ramsey, MD, PhD, Center for Cost and Outcomes Research, University of Washington, 146 North Canal St, Suite 300, Seattle, WA 98103; e-mail: s-ramsey{at}u.washington.edu

Effective outpatient management of COPD requires prescription of and adherence to appropriate therapies. Although practice guidelines for outpatient management of COPD are widely available, evidence suggests that these guidelines are not being implemented widely in clinical practice. Furthermore, several studies have shown that patient compliance with recommended therapy is poor. This paper discusses several reasons why implementation of practice guidelines and adherence with prescribed therapies may be poor. Potential clinical and economic consequences of suboptimal management are reviewed. Although the evidence suggests that improved compliance with guideline-recommended practice will improve symptoms and disease-specific quality of life, further work needs to be done to establish the cost-effectiveness of chronic therapies for COPD relative to other chronic conditions. Without such data, managed care organizations will be reluctant to allocate scarce resources toward expensive guideline implementation programs for individuals with this condition.

Key Words: compliance • COPD • prescription use

This article has been cited by other articles:

				S. R. Salpeter, N. S. Buckley, T. M. Ormiston, and E. E. Salpeter Meta-Analysis: Effect of Long-Acting {beta}-Agonists on Severe Asthma Exacerbations and Asthma-Related Deaths Ann Intern Med, June 20, 2006; 144(12): 904 - 912. [Abstract] [Full Text] [PDF]

				A. O. D'Souza, M. J. Smith, L. A. Miller, and J. Kavookjian An Appraisal of Pharmacoeconomic Evidence of Maintenance Therapy for COPD Chest, June 1, 2006; 129(6): 1693 - 1708. [Abstract] [Full Text] [PDF]

				B J Smith, K Dalziel, H J McElroy, R E Ruffin, P A Frith, K A McCaul, and F Cheok Barriers to success for an evidence-based guideline for chronic obstructive pulmonary disease Chronic Respiratory Disease, July 1, 2005; 2(3): 121 - 131. [Abstract] [PDF]

				C B Cooper and D P Tashkin Recent developments in inhaled therapy in stable chronic obstructive pulmonary disease BMJ, March 19, 2005; 330(7492): 640 - 644. [Full Text] [PDF]

				L. D. Snyder and M. D. Eisner Obstructive Lung Disease Among the Urban Homeless Chest, May 1, 2004; 125(5): 1719 - 1725. [Abstract] [Full Text] [PDF]

				D. Brooks, B. Krip, S. Mangovski-Alzamora, and R.S. Goldstein The effect of postrehabilitation programmes among individuals with chronic obstructive pulmonary disease Eur. Respir. J., July 1, 2002; 20(1): 20 - 29. [Abstract] [Full Text] [PDF]

				A. O'BRIEN, P. RUSSO-MAGNO, A. KARKI, S. HIRANNIRAMOL, M. HARDIN, M. KASZUBA, C. SHERMAN, and S. ROUNDS Effects of Withdrawal of Inhaled Steroids in Men with Severe Irreversible Airflow Obstruction Am. J. Respir. Crit. Care Med., August 1, 2001; 164(3): 365 - 371. [Abstract] [Full Text] [PDF]